Access to out-of-spec melanoma cell therapy
Part of Cancer, Skin clinical trials.
This program provides access to AMTAGVI, a personalized cell therapy for melanoma, for patients whose manufactured product did not meet commercial release standards but was deemed safe. It aims to offer treatment when no other options are available.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been prescribed AMTAGVI for your melanoma and have a manufactured product that did not meet commercial release standards.
- You must not have had a severe allergic reaction to certain chemotherapy drugs or components of the cell therapy product.
- You must not have an ongoing infection or serious heart, lung, or kidney problems that would make treatment unsafe.
- You must not be pregnant or breastfeeding, and if you or your partner can have children, you must agree to use highly effective birth control during treatment and for 12 months after.
- Your doctor must confirm that you are medically stable enough to receive the treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests using your own immune cells (TILs) to fight advanced uveal melanoma, undifferentiated pleomorphic sarcoma, dedifferentiated liposarcoma, or angiosarcoma. It aims to see if this treatment can shrink tumors or slow their growth.
This Phase 1 study tests a gene-modified immune cell treatment for advanced cancers that don’t have standard curative options. It may help by attacking cancer cells that show a specific marker called IL13Rα2 after patients receive “conditioning” chemotherapy to prepare the immune system.
This trial tests a new combination treatment, IOV-3001 and lifileucel, for people with advanced melanoma that has not responded to standard immunotherapy and cannot be surgically removed. It aims to see if this cellular therapy is safe and effective.
This trial gives people who have been prescribed TECELRA (a cell therapy for certain cancers) a chance to receive their dose even if it didn't meet quality standards. It's for patients who have no other way to get this treatment.
This program provides access to an experimental CAR-T cell therapy called cilta-cel for people with multiple myeloma who have run out of other good options. It is designed for those who qualify for the standard treatment but need special handling because their cell product is out of specification.
This trial tests a new way to guide treatment with your own immune cells (called TIL therapy) using a special PET scan to see which tumors might respond best. It aims to make the treatment more effective for people with advanced melanoma that has not responded to previous therapies.
Hear when a new Unresectable Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.